Logo Logo
Hilfe
Hilfe
Switch Language to English
Ewers, Michael; Brendel, Matthias; Rizk-Jackson, Angela; Rominger, Axel; Bartenstein, Peter; Schuff, Norbert; Weiner, Michael W. (2014): Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. In: Neuroimage-Clinical, Vol. 4: S. 45-52
[img]
Vorschau
2MB

Abstract

Brain changes reminiscent of Alzheimer disease (AD) have been previously reported in a substantial portion of elderly cognitive healthy (HC) subjects. The major aim was to evaluate the accuracy of MRI assessed regional gray matter (GM) volume, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET),and neuropsychological test scores to identify those HC subjects who subsequently convert to mild cognitive impairment (MCI) or AD dementia. We obtained in 54 healthy control (HC) subjects a priori defined region of interest (ROI) values of medial temporal and parietal FDG-PET and medial temporal GM volume. In logistic regression analyses, these ROI values were tested together with neuropsychological test scores (free recall, trail making test B (TMT-B)) as predictors of HC conversion during a clinical follow-up between 3 and 4 years. In voxelbased analyses, FDG-PET and MRI GM maps were compared between HC converters and HC non-converters. Out of the 54 HC subjects, 11 subjects converted to MCI or AD dementia. Lower FDG-PET ROI values were associated with higher likelihood of conversion (p = 0.004),with the area under the curve (AUC) yielding 82.0% (95% CI = (95.5%,68.5%)). The GM volume ROI was not a significant predictor (p = 0.07). TMT-B but not the free recall tests were a significant predictor (AUC = 71% (95% CI = 50.4%,91.7%)). For the combination of FDG-PET and TMT-B, the AUC was 93.4% (sensitivity = 82%,specificity = 93%). Voxel-based group comparison showed reduced FDG-PET metabolism within the temporo-parietal and prefrontal cortex in HC converters. In conclusion, medial temporal and-parietal FDG-PET and executive function show a clinically acceptable accuracy for predicting clinical progression in elderly HC subjects. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.